Evogene Ltd., an Israel-based biotech company specializing in agriculture and human health, reported a 54.7% revenue decline in 2025 to $3.85 million from $8.51 million in 2024, reflecting shifts in licensing arrangements including the termination of Lavie Bio's bio-fungicide license with Corteva Agriscience. Despite continued net losses, which narrowed to $7.83 million in 2025, the company maintains a solid cash position of $12.96 million supporting ongoing R&D investments. Key growth drivers include the exclusive license of microbiome therapeutic BMC128 to Shanghai Lishan Biopharmaceuticals and government-sponsored research consortia, while regulatory constraints under Israeli Innovation Law present operational challenges. Capital raised through warrant exercises in early 2026 strengthens the balance sheet for future initiatives.